We mapped recessive deafness *DFNB63* (OMIM 611451) segregating in eight families to a 2.04 cM interval on human chromosome 11q13.3-q13.4 (refs [@R5]--[@R7]). This interval includes *FGF3* and mutations of this gene cause a form of syndromic deafness (OMIM 610706) characterized by microtia, microdontia and inner ear agenesis^[@R8],[@R9]^. Three of the eight families were found to co-segregate recessive mutations of *FGF3* with all of the features of this syndrome. We used the meiotic recombinations from the five *FGF3* mutation-negative families to refine the linkage interval of *DFNB63* to 1.03 Mb ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"} online). This interval has 26 annotated and predicted genes (NCBI build 36.1; <http://genome.ucsc.org>). Using genomic DNA from affected members, we sequenced the protein-coding and non-coding exons and approximately 100 bp flanking each exon of all 26 genes. We discovered four pathogenic mutations in an uncharacterized gene *LRRC51*, renamed *LRTOMT* ([Fig. 1a](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). Using primers designed to hybridize to *LRRC51* exons annotated in build 36.1, we determined the complete exon content of *LRTOMT* by RT-PCR and 5' and 3' RACE analyses using adult human liver cDNA ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"} online). We found a total of 10 exons comprising five different alternatively spliced transcripts of *LRTOMT* that are widely expressed ([Fig. 1a and b](#F1){ref-type="fig"}). Surprisingly, exons 5, 7 and 8 are included in transcripts encoding two different proteins: LRTOMT1 and LRTOMT2. These exons are predicted to be translated in two alternative reading frames (dual reading frames) and encode either the C-terminus of LRTOMT1 or the N-terminus of LRTOMT2 ([Fig. 1a](#F1){ref-type="fig"} and [Supplementary Fig. 3](#SD1){ref-type="supplementary-material"} online). When translation of transcript D/D′ starts in exon 3 ([Fig. 1c](#F1){ref-type="fig"}), the encoded protein has two leucine-rich repeats and is named LRTOMT1 ([Fig. 1a](#F1){ref-type="fig"} and [Supplementary Fig. 4](#SD1){ref-type="supplementary-material"} online). Translation beginning in exon 5 ([Fig. 1d](#F1){ref-type="fig"}) produces LRTOMT2, which is predicted to have a catechol-*O*-methyltransferase domain. Depending on the use of an alternative acceptor splice site in exon 8, LRTOMT2 can have a predicted transmembrane helix as well ([Fig. 1a](#F1){ref-type="fig"} and [Supplementary Fig. 5](#SD1){ref-type="supplementary-material"} online). *In silico* analyses predict that 7% of alternatively spliced human genes have at least one exon that is translated in different reading frames^[@R10]--[@R14]^. However, there are few well-studied examples of dual reading frame transcripts of genes in higher organisms^[@R13],[@R15]^.

The homozygous mutation (c.358+4G\>A) in hearing-impaired individuals of family TR57 alters the splice donor site of exon 8 of *LRTOMT* ([Fig. 1a](#F1){ref-type="fig"}, [Table 1](#T1){ref-type="table"} and [Supplementary Fig. 6](#SD1){ref-type="supplementary-material"} on line). RT-PCR analysis of *LRTOMT* revealed that exon 8 was absent in lymphoblastoid RNA transcripts of affected individuals ([Supplementary Fig. 6b](#SD1){ref-type="supplementary-material"} online). The absence of exon 8 results in a reading frameshift and a premature downstream translation stop codon (p.A29SfsX54) within the mRNA encoding LRTOMT2. Affected individuals of families FT1A-G, FT2 ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"} online) and PKDF702 (ref [@R6]) are homozygous for transition mutations c.242G\>A (p.R81Q), c.313T\>C (p.W105R), and c.328G\>A (p.E110K), respectively ([Fig. 1a](#F1){ref-type="fig"}, [Table 1](#T1){ref-type="table"}, and [Supplementary Fig. 6](#SD1){ref-type="supplementary-material"} online). All three amino acid substitutions in LRTOMT2 are nonconservative^[@R16]^, are predicted to alter the catechol-*O*-methyltransferase domain of LRTOMT2 ([Fig. 1a](#F1){ref-type="fig"}), and the wild type residues are evolutionarily conserved down to fugu ([Supplementary Fig. 5](#SD1){ref-type="supplementary-material"} online). All four mutations of *LRTOMT* co-segregate with deafness in these families, carriers have normal hearing, and none of the four mutations was detected in ethnically matched normal-hearing subjects ([Table 1](#T1){ref-type="table"}).

Catechol-*O*-methyltransferase (COMT, EC 2.1.1.6) catalyzes the transfer of a methyl group from S-adenosyl-L-methionine (AdoMet) to a hydroxyl group of catechols^[@R17]^. The crystal structure of rat COMT (39% identity and 60% similarity to LRTOMT2 for 212 amino acids) was used to model the catechol-*O*-methyltransferase domain of human LRTOMT2 for prediction of the effect of the missense mutations on this domain ([Fig. 2](#F2){ref-type="fig"}). The three mutated residues are in helix 1 (p.R81Q), in helix 2 (p.W105R), and in the loop that follows helix 2 (p.E110K), and thus not in the hypothetical substrate-binding pockets. However, this loop is predicted to be important for the groove that binds the putative methyl acceptor^[@R17]^. The p.R81 and p.E110 residues are predicted to form a salt bridge and hydrogen bonds between helix 1 and the loop, while p.W105 is predicted to make hydrophobic interactions in the core between the helices ([Fig. 2b-d](#F2){ref-type="fig"}). These residues may therefore be important for protein stability and could indirectly affect the substrate-binding region^[@R17]^.

Deafness may be due to the predicted destabilizing effects of all four mutations on the catechol-*O*-methyltransferase domain of LRTOMT2, but we cannot exclude the possibility that it is due to alterations of LRTOMT1 isoforms D and E. While two of the mutations are located in the 3'UTR of mRNA encoding LRTOMT1 isoforms D and E, and a third is predicted to result in a synonymous substitution (p.A215A), all three could affect mRNA stability or regulation in ways that are difficult to predict. The splice site mutation is predicted to cause a frameshift mutation in mRNAs for both LRTOMT2 and LRTOMT1 ([Table 1](#T1){ref-type="table"}).

An animal model of *LRTOMT* would be valuable in evaluating the pathophysiology of these mutations. However, in rodents, there are two separate genes designated *Lrrc51* and *Tomt* ([Fig. 3a](#F3){ref-type="fig"}), which together are orthologous to primate *LRTOMT.* We were unable to detect fusion transcripts of mouse or rat *Lrrc51* and *Tomt* by RT-PCR analysis of brain, liver and heart cDNA ([Fig. 3a](#F3){ref-type="fig"}) using eight different 5' and 3' RACE primers as well as all possible combinations of five forward primers in *Lrrc51* and six reverse primers in *Tomt* (arrowheads, [Fig. 3a](#F3){ref-type="fig"}). *LRTOMT* fusion transcripts could be readily amplified from human liver and heart cDNAs ([Fig. 1a and b](#F1){ref-type="fig"}).

Five different primates express transcripts that include nearly all of the exons of *LRTOMT* as well as a separate transcript equivalent to rodent *Lrrc51* ([Supplementary Fig. 7](#SD1){ref-type="supplementary-material"} online). Inspection of the mouse genome reveals that, in a hypothetical fusion transcript between *Lrrc51* and *Tomt*, if the first translation start codon (ATG in exon 5) were to be used in rodents, an inframe translation stop codon would be present four codons downstream ([Fig. 1d](#F1){ref-type="fig"}). A fusion protein between LRRC51 and TOMT in rodents is also unlikely because the first exon of *Tomt* does not have an inframe consensus splice acceptor site ([Supplementary Fig. 2c](#SD1){ref-type="supplementary-material"} online).

Mouse *Lrrc51* has six exons and is predicted to encode LRRC51, a 253 residue protein that has two leucine-rich repeats ([Fig. 3a](#F3){ref-type="fig"}). The four exons of mouse *Tomt* are predicted to encode TOMT (258 residues), which has one transmembrane helix and a catechol-*O*-methyltransferase domain ([Fig. 3a](#F3){ref-type="fig"}). An amino acid sequence comparison between mouse LRRC51 and human LRTOMT1 shows 85% identity (93% similarity; [Supplementary Fig. 4](#SD1){ref-type="supplementary-material"} online). A comparison between mouse TOMT and isoform D′ (residues 34 to 291) of human LRTOMT2 shows 91% amino acid identity (92% similarity; [Supplementary Fig. 5](#SD1){ref-type="supplementary-material"} online). RT- PCR and sequence analyses of cDNAs from mouse embryos and adult tissues showed wide expression of *Lrrc51* and *Tomt* ([Fig. 3b](#F3){ref-type="fig"}).

We next examined embryonic expression of mouse *Lrrc51* and *Tomt* using *in situ* hybridization. *Lrrc51* mRNA is expressed in the developing choroid plexus from embryonic day 12.5 (E12.5) onwards and in the epithelium of the developing airway tract from E14.5 onwards (data not shown), and it is detected in the postnatal inner ear by RT-PCR ([Fig. 3b](#F3){ref-type="fig"}). *Tomt* expression was not detected anywhere in the embryo at E12.5, while at E14.5 a specific signal is apparent in the developing inner ear. At E16.5, there is expression in the utricle and saccule (data not shown). Detailed images of the cochlear and vestibular epithelia at E18.5 show that *Tomt* is expressed specifically in the region of the sensory cells of the cochlea, utricle, saccule and crista ampullaris ([Fig. 3c--e](#F3){ref-type="fig"}).

In Western blot analyses of protein extracts from P7 mouse cochlea, retina and P40 heart, antisera against LRRC51 detected two bands ([Fig. 4a](#F4){ref-type="fig"}). Similar size proteins were found for LRTOMT1 in human liver, kidney and spleen ([Fig. 4b](#F4){ref-type="fig"}). Antisera directed against mouse TOMT showed one major band of approximately 28--30 kDa in the cochlea and heart ([Fig. 4c](#F4){ref-type="fig"}), similar to the deduced size of 28.8 kDa from the amino acid sequence of mouse TOMT isoform a ([Fig. 3a](#F3){ref-type="fig"}). Using protein from human liver and kidney, antisera to mouse TOMT recognized a 38 kDa LRTOMT2 ([Fig. 4d](#F4){ref-type="fig"}), which we hypothesize is isoform D′ (32.2 kDa deduced). Taken together, RT-PCR, RACE, and Western blot analyses are consistent with the annotation of mouse *Lrrc51* and *Tomt* as separate genes encoding two different proteins and human LRTOMT as a larger fusion gene with transcripts that are indeed translated in two different reading frames giving rise to LRTOMT1 and LRTOMT2, which have no sequence similarity to one another.

To determine the cellular and subcellular localization of LRRC51 and TOMT, we performed immunofluorescence confocal microscopy on mouse inner ear. LRRC51 immunoreactivity was detected with both antisera PB837-K and PB837-T in the cytoplasm of vestibular hair cells and supporting cells (data not shown) as well as in inner (IHC) and outer hair cells (OHCs) of the organ of Corti ([Fig. 5a-c](#F5){ref-type="fig"}). In OHCs, immunoreactivity of LRRC51 was most prominent along the basolateral wall and distributed throughout the cytoplasm. OHCs have a high density of voltage-sensitive prestin motors in their lateral plasma membranes^[@R18],[@R19]^ that power somatic electromotility^[@R20]^ and a complex cortical lattice connected to the plasma membrane by pillars^[@R21]--[@R23]^. LRRC51 may have a special function as a component of the OHC lateral wall.

TOMT was detected in the cytoplasm of IHCs and OHCs and their supporting cells ([Fig. 5d-f](#F5){ref-type="fig"}) as well as in vestibular hair cells and their supporting cells (data not shown) in adult mouse. In the OHCs of the organ of Corti, TOMT was concentrated under the cuticular plate in a manner similar to LRRC51. TOMT immunoreactivity was also observed in outer phalangeal (Deiters) cells, in particular along the length of plasma membrane of their phalangeal processes. The homology between LRTOMT2 and COMT and the conservation of the majority of the amino acids that are involved in substrate binding^[@R17],[@R24]^ suggest that LRTOMT2 might function as a catechol-*O*-methyltransferase^[@R25]^. Residual methyltransferase activity in COMT-deficient mice was hypothesized to be derived from an as yet unidentified methyltransferase^[@R26]^, which might be TOMT. Identification of *LRTOMT*, which encodes both a leucine rich protein and a methyltransferase opens an exciting new field for genetic and physiological studies of the inner ear.

*LRTOMT* is the first example, to our knowledge, of a human gene that exhibits transcription mediated gene fusion and has dual reading frames, although the latter phenomenon is predicted to be common^[@R10]^, and may have implications for understanding hereditary disorders. In some cases, unrecognized alternative reading frames may account for pleiotropy as well as phenotypic variation among alleles of other genes.

The selective pressures and adaptive benefits, if any, that give rise to a fusion gene such as *LRTOMT* are yet to be determined. Transcription-induced chimerism of two neighboring genes can generate bifunctional, multi-domain proteins^[@R10]^. An additional benefit may be tight co-expression of functionally related proteins^[@R11]^, which might be true for LRTOMT1 and LRTOMT2, since the mouse orthologs, LRRC51 and TOMT, are both expressed in hair cells. Because *Lrrc51* and *Tomt* are separate transcription units it will be a challenge to model DFNB63 mutations of *LRTOMT* in the mouse.

METHODS {#S1}
=======

Subjects and clinical evaluations {#S2}
---------------------------------

Institutional Review Boards (IRBs) at the National Center of Excellence in Molecular Biology, Lahore, Pakistan (FWA00001758) and the NIDCD/NINDS at the National Institutes of Health, USA (OH-93-N-016) approved this study. Approval was also obtained from the ethics committees of the medical faculty of the Karadeniz Technical University in Trabzon, Turkey, the Radboud University Nijmegen in The Netherlands and the University Hospital of Sfax in Tunisia. Written informed consent was obtained from all adult participants and from parents of subjects younger than 18 years of age. The Pakistani, Turkish and Tunisian families and some of the clinical data were previously reported^[@R5]--[@R7]^. Unpublished Tunisian families segregating nonsyndromic deafness linked to markers on chromosome 11q13.2-q13.3 are shown in [Supplementary Fig. 1](#SD1){ref-type="supplementary-material"} (online).

Several participating family members underwent otoscopic examination, pure-tone audiometry and vestibular function testing as previously described^[@R5]--[@R7]^. MRI or CT-scan analyses were performed to examine inner ear structure of two affected individuals and one normal hearing individual of Pakistani families segregating recessive mutations of *FGF3* or *LRTOMT*.

Genetic Linkage and Mutation Analysis Studies {#S3}
---------------------------------------------

Protocols for linkage analyses were described previously^[@R5]--[@R7]^. All exons and intron-exon boundaries of 26 candidate genes in the refined *DFNB63* interval were amplified under standard PCR conditions. Sequences of primers used for the amplification of *LRTOMT* are given in [Supplementary Table 1](#SD1){ref-type="supplementary-material"} (online) and sequence analysis was performed using an ABI 3730 instrument as described earlier^[@R27]--[@R28]^. Control DNAs from 88 to 182 normal-hearing Pakistani, Tunisian or Turkish individuals were used to determine mutant allele frequencies ([Table 1](#T1){ref-type="table"}).

cDNA cloning and sequence analysis {#S4}
----------------------------------

PCR-ready adult human liver cDNA (Ambion) was used for cloning full-length isoforms of *LRTOMT.* Poly(A)^+^ RNA was isolated (Poly(A)Pure, Ambion) from postnatal day 1 (P1) to P5 inner ear tissue dissected from 50 C57BL/6J mice and cDNA was synthesized using an oligo-dT primer and PowerScript reverse transcriptase (Clontech). We used premade adult mouse brain, heart, liver and rat brain cDNAs and Marathon-Ready cDNAs (Clontech). For chimpanzee, rhesus, baboon and lemur, the isoforms of *LRTOMT* were evaluated using cDNAs prepared from total RNA isolated from brain tissue obtained from the Southwest National Primate Research Center and the Duke Lemur Center. Rhesus brain PCR-ready cDNA was also obtained from CytoMol. All PCR products were subcloned and both strands were fully sequenced. The sequences of primers used to PCR amplify cDNA for *LRTOMT*, *Lrrc51*, and *Tomt* from human, chimpanzee, rhesus, baboon, lemur, and rat tissues are provided in [Supplementary Table 2](#SD1){ref-type="supplementary-material"} (online).

RT-PCR analysis {#S5}
---------------

Lymphoblast cell lines were established by EBV transformation of peripheral-blood cells from deaf Turkish subjects and control individuals. Total RNA from these cells was isolated using the RNeasy Midi Kit (Qiagen). Subsequently, cDNA synthesis was performed according to standard procedures using random hexamers. PCR reactions were performed with gene-specific primers designed from sequences in exons 7 and 10 ([Supplementary Table 2](#SD1){ref-type="supplementary-material"} online). To evaluate splicing of exon 8 of *LRTOMT*, PCR fragments were isolated from agarose gel and the sequence was verified. For multiple tissue PCR analyses, we used cDNA panels (Clontech) synthesized using the tissues from humans 19 to 69 years old and from mice 8 to 12 weeks old. RNA from human fetal heart, skeletal muscle, liver and lung was obtained from Clontech. cDNA from human fetal cochlear RNA (16 to 22 weeks gestation) was synthesized as described^[@R28]^.

Molecular modeling {#S6}
------------------

The crystal structure of rat COMT was used as a template (pdb-code 1h1d) to build a model of the catechol-*O*-methyltransferase domain of the human LRTOMT2 ([Fig. 2](#F2){ref-type="fig"}). The WHAT IF-server (<http://swift.cmbi.ru.nl>) was used for modeling. Energy minimization and analysis were done with Yasara (<http://www.yasara.org>). For the modeled region (residues 79-290) of LRTOMT2, there is 39% sequence identity with rat COMT. The alignment and a rotating figure of the model is available on <http://www.cmbi.ru.nl/~hvensela/catechol>.

Digoxigenin cRNA *in situ* hybridization {#S7}
----------------------------------------

Sense and antisense probes for RNA *in situ* hybridization correspond to the 3' ends of murine *Tomt* and *Lrrc51*. PCR reactions to amplify cDNA were carried out on mouse total brain cDNA using primers given in [Supplementary Table 2](#SD1){ref-type="supplementary-material"} (online). Amplimerswere cloned in both orientations into pCR2.1 using the TOPO TA Cloning Kit (Invitrogen) and sequenced with T7 and M13 primers. Subsequently, PCR reactions were performed with T7 and M13 vector primers using the pCR2.1 constructs as a template.Digoxigenin (DIG)-cRNA probes were generated by using these PCR products, and *in situ* hybridizations were performed as described previously^[@R28]^. The use of animals was performed under the approval of the animal experiment committee of Utrecht University.

Antibodies, Immunocytochemistry, and Western blot analysis {#S8}
----------------------------------------------------------

LRRC51 (PB837-K and PB837-T) and TOMT (PB840-L & PB840-R) antisera were raised in rabbit against the following synthetic peptides (Princeton BioMolecules): KRMGIKPKKVRAKQD (PB837-K), TGLRPVRHSKSGKSLT (PB837-T), IPRLRAQHQLNRADL (PB840-L) and RPRYYLRDLQLLEAHAL (PB840-R) (Genbank accession number pending). Antisera were affinity purified using AminoLink columns (Pierce Biotechnology) with beaded agarose to which we coupled the corresponding synthetic peptide used as the immunogen. A fluorescein-conjugated anti-rabbit IgG secondary antibody was obtained from Amersham Pharmacia Biotech. Specificities of antibodies were determined by Western blot analyses and peptide blocking experiments ([Supplementary Fig. 8](#SD1){ref-type="supplementary-material"} online). No signal was detected when the primary antibody was preincubatedfor 2 hr at room temperature with an excess of the immunizingpeptide. Immunocytochemistry was performed as described previously^[@R29]^.

For Western blot analyses, cochlea, retina and heart from C57BL/6J mice (7 and 40 days old) were sonicated in ice-cold protease inhibitor cocktail (Calbiochem Biosciences). Protein was extracted by boiling for 5 min in SDS-PAGE sample buffer (0.125M Tris-HCl, 20% glycerol, 4% SDS, 0.005% bromophenol blue). A 50 μg protein sample was separated on a 10% Bis-Tris gel (Invitrogen) and transferred to PVDF membrane (Millipore) for Western blot analyses as described^[@R30]^. Novex Sharp protein standard cat \# LC5800 (Invitrogen) and Precision Plus Protein Prestained Standards Cat\# 161-0375 (Bio Rad) were used for mouse and human tissue blots, respectively. For animal experiments approval was obtained by the NINDS/NIDCD Animal Care and Use Committee (protocol 1263-06).
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![*LRTOMT* has alternative reading frames, and mutations cause nonsyndromic deafness. (**a**) *LRTOMT* has ten exons encoding multiple isoforms. Exons 5, 7 and 8 have dual reading frames. The two different reading frames of *LRTOMT* are colored orange and green. *LRTOMT* has two predicted translation start-codons, one in exon 3 and the second in exon 5. Grey boxes denote UTRs, and arrows show the location of primer-pairs for expression analyses. Isoforms A to E of LRTOMT1 have one predicted transmembrane domain (TM) and two leucine-rich repeats. Transcripts D′ and E′ are identical in sequence to D and E, respectively, but encode an entirely different protein, LRTOMT2, when translation starts in exon 5 and stops in exon 10. LRTOMT2 isoform D′ has a predicted catechol-*O*-methyltransferase domain and a TM. (**b**) PCR analyses of cDNAs from adult and fetal human tissues using primer-pairs shown in panel **a**. Transcripts A and C are amplified using primers F1 and R1 and are detected in all adult tissues tested. The transcripts D/D′ and E/E′ were detected either using RT-PCR primers F2 and R2 (adult tissues) or primers F3 and R3 (fetal tissues). (**c-d**) ClustalW alignments of nucleotide sequences of *LRTOMT* exons 3 and 5 and *Lrrc51*. Conserved translation start-codons of LRTOMT1 and LRTOMT2 are boxed. (**d**) If translation begins with the conserved ATG in exon 5 of mouse, dog, horse and opossum, there is an inframe translation stop-codon (TAG, red font).](nihms390775f1){#F1}

![Molecular model and predicted effects of missense mutations. (**a**) Molecular model of the catechol-*O*-methyltransferase domain of LRTOMT2, residues 79-290. The mutated residues are depicted in blue. The predicted ligands are colored yellow, and the tyrosine residue (p.Y111) that lines the hydrophobic groove of the ligand binding site is shown in cyan. The region enlarged in b-d is boxed. (**b-d**) Missense mutations of LRTOMT2. The region of helices 1 and 2 and part of the flanking loops is enlarged. Wild type residues p.R81, p.W105 and p.E110 are depicted in blue, mutated residues in pink. Hydrogen bonds are represented by yellow dotted lines. **(b)** The p.R81 and p.E110 residues form a salt bridge between helix 1 and the loop following helix 2. The p.Q81 residue cannot form this salt bridge as it is not positively charged. Also, the formation of hydrogen bonds is impaired due to the smaller size of glutamine as compared to arginine. (**c**) The p.W105 residue is predicted to make hydrophobic interactions due to its big side chain. Most of these interactions would be lost by the p.W105R substitution. (**d**) Mutation p.E110K is predicted to lead to the loss of hydrogen bonds and a salt bridge. There would likely be repulsion between the side chains p.K110 and p.R81 since both are positively charged. h1, helix 1; h2, helix 2; l, loop](nihms390775f2){#F2}

![Mouse *Lrrc51* and *Tomt* (**a**) Chromosomal region 7qE3 is syntenic to human chromosome 11q13.3. Unlike humans, mouse has two separate genes, *Lrrc51* and *Tomt* encoding LRRC51 and TOMT, respectively. Translation of *Tomt* mRNA starts in exon 2. This ATG of *LRTOMT* is conserved in primates and located in human exon 8 ([Supplementary Fig. 2d](#SD1){ref-type="supplementary-material"} online). Right pointing arrowheads in exons 1--5 of *Lrrc51* indicate forward RT-PCR primers used in all possible combinations with reverse primers (left pointing arrowheads) in *Tomt* and cDNAs from mouse brain, liver and heart. No mouse fusion transcripts were recovered (data not shown). Arrows (f1, r1 and f2, r2) indicate primer-pairs for expression profiling in **b**. (**b**) PCR analyses of *Lrrc51* and *Tomt* transcripts show ubiquitous expression. (**c-e**) *Tomt* sense and antisense cRNA probes were hybridized to sagittal sections of whole mouse embryos from embryonic day 12.5 to 18.5. No signal was detected using the control sense probe (data not shown). (**c**) At E18.5 specific staining is visible in the region of the sensory cells of the cochlea where outer hair cells (arrowhead 1) and inner hair cells (arrowhead 2) are located. (**d**) At E18.5 in the utricle (arrow) and saccule (arrowhead), a clear signal can be observed in the region of the sensory cells. (**e**) In E18.5 sensory epithelium of the cristae ampullaris, *Tomt* mRNA was detected (arrow). No other tissues showed staining for *Tomt* at E18.5. Scale bars, 100 μm. sm, scala media; ec, endolymph compartment.](nihms390775f3){#F3}

![Western blot analyses of mouse LRRC51 and TOMT, and human LRTOMT1 and LRTOMT2. **(a)** Western blot analyses using anti-mouse LRRC51, PB837 (K+T) antisera and protein extracts from 7 day old (P7) mouse cochlea and retina (50 μg protein/lane) showed two bands of a size somewhat larger than the predicted sizes for LRRC51 protein isoforms A and B, while in P40 heart, the lower molecular weight isoform was detected along with a \~16 kDa band that might represent isoform C. (**b**) In human tissue, PB837 (K+T) detected proteins also of a size somewhat larger than predicted for human LRTOMT1 (isoform A, B and C). (**c**) Western blotting of anti-mouse TOMT (PB840-L) using affinity-purified antisera and mouse cochlear protein extracts (P3; 50 μg/lane) showed one band of about the expected size. In protein extracts from P40 heart, one \~28 kDa band of the expected deduced size (28.8 kDa) was detected. (**d**) Western blot analysis of protein from human tissues using anti-mouse TOMT antibodies (PB840 L+R) showed a signal in liver and kidney at \~37 kDa, slightly larger than the predicted size of 32.2 kDa for LRTOMT2 (isoform D′).](nihms390775f4){#F4}

![Immunolocalization of LRRC51 and TOMT in the P30 mouse inner ear (**a**) Anti-LRRC51 antiserum PB837 (green) immunostained the basolateral wall of the outer hair cells (OHCs), producing an annular fluorescence pattern in the optical cross-section of whole mount organ of Corti at the level of OHC nuclei. (**b**) Optical cross-section at the level below the cuticular plate of OHCs. Immunoreactivity to PB837-T antibody is observed at the lateral wall and in the cytoplasm of OHCs with a concentration at the site corresponding to the smooth endoplasmic reticulum. A weaker signal can also be observed in cytoplasm of inner hair cells (IHCs). (**c)** Longitudinal view of OHC bodies stained with PB837-K antibody highlighting the basolateral wall of OHCs. OHC nuclei are not stained. (**d**) Confocal images of the optical cross-section of the whole mount organ of Corti at the level of OHC nuclei immunostained with anti-mouse TOMT antibody. Cytoplasmic staining around the nuclei is seen, which is more evident in (**e**). Immunoreactivity is also observed in the cytoplasm of external sulcus cells (ESCs) and in phalanges (Ph) of outer phalangeal cells. (**e**) Optical cross-section at the level above the nuclei of OHCs. Immunoreactivity to PB840-L antibody in outer and inner hair cell bodies is concentrated under the cuticular plate of OHCs where smooth endoplasmic reticulum is located. (**f**) Longitudinal view of OHC bodies showing TOMT concentrated in the cytoplasm of OHCs above the nuclei. An arrow indicates staining of the phalanges (Ph) of outer phalangeal cells. The red signals represent rhodamine-phalloidin staining of F-actin. Scale bars, 5 μm.](nihms390775f5){#F5}

  Family    Ethnicity   Gene                               Mutation (nt) LRTOMT2[a](#TFN1){ref-type="table-fn"}   Mutation (aa) LRTOMT2   Mutation (nt) LRTOMT1[a](#TFN1){ref-type="table-fn"}   Mutation (aa) LRTOMT1   Allele frequency[b](#TFN2){ref-type="table-fn"}
  --------- ----------- ---------------------------------- ------------------------------------------------------ ----------------------- ------------------------------------------------------ ----------------------- -------------------------------------------------
  TR57      Turkish     *LRTOMT*                           c.358+4G\>A                                            p.A29SfsX54             c.761+4G\>A                                            p.G163VfsX4             0/176
  FT1A-G    Tunisian    *LRTOMT*                           c.242G\>A                                              p.R81Q                  c.645G\>A                                              p.A215A                 0/190
  FT2       Tunisian    *LRTOMT*                           c.313T\>C                                              p.W105R                 c.716T\>C                                              3' UTR                  0/180
  PKDF702   Pakistani   *LRTOMT*                           c.328G\>A                                              p.E110K                 c.731G\>A                                              3' UTR                  0/364
  PKDF537   Pakistani   [\*](#TFN3){ref-type="table-fn"}                                                                                                                                                                 

Nucleotide changes are numbered according to the first coding ATG (Accession numbers EU627069, EU627070).

Ethnically matched hearing subjects.

In family PKDF537, no pathogenic mutations were found either in the coding region of *FGF3, LRTOMT* or in 25 evolutionary conserved regions in the introns of *LRTOMT*, suggesting that the mutation might be in a nonconserved region of an intron, in a distant regulatory element, or in another gene in the *DFNB63* interval. Alternatively, the hearing loss segregating in this large family may have been spuriously linked to chromosome 11q13.3 despite a LOD score of 6.98.

[^1]: These authors contributed equally to this work. Correspondence should be addressed to H.K.
